Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Paul Barr who wrote (2693)	11/8/1997 12:05:00 AM
From: Oliver & Co	Read Replies (2) \| Respond to of 6136

This is just a new formulation of Saquinavir, the least potent of the PIs, shows antagonism with Indinavir in Vitro. Shows good results in combination with other PIs. Not a good single PI choice, unless you mix it with Rescriptor. Best adherence is when regimens are kept as simple as possible, with as few pills as possible. Also remember resistance and cross-resistance. Beware the "Sins from the Past". If you give SQV and develop resistance, there may be cross-resistance to the other PIs. You must try first the one with the lowest cross-resistance possible. This will be good for "Salvage Therapy". JLL